Signal #144890 · SEC 8-K

$FLNA SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $FLNA filing catalyst

Why did $FLNA trigger an AI stock catalyst alert?

$FLNA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +0.5/10). Headline: Filana Therapeutics Reports Q3 Results; Phase 2a Screening to Start by Q1 2027. Key points: - Total operating expenses were $11.2M in Q3 2026 compared to $11.8M in Q3 2025. - Operating loss for the quarter reached $11.2M as R&D spend was $3.87M. - Patient screening in Phase 2a TSC-related epilepsy study expected by Q1 2027 following FDA hold lift.

How did $FLNA stock react after the SEC filing?

After the SEC 8-K for $FLNA, observed market reaction: T0 price $0.57. Past moves do not guarantee future results.

Where can I get real-time $FLNA SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $FLNA via Telegram and the VIP Web Terminal from €10/month.

$FLNA

$FLNA – Filana Therapeutics Reports Q3 Results; Phase 2a Screening to Start by Q1 2027

FILANA THERAPEUTICS, INC.

2026-11-05 00:00:00 UTC · SEC 8-K · All $FLNA

Unlocked archive · Analyzed in <2s at T0

Neutral AI Sentiment (+0.5 / 10)

Total operating expenses were $11.2M in Q3 2026 compared to $11.8M in Q3 2025.
Operating loss for the quarter reached $11.2M as R&D spend was $3.87M.
Patient screening in Phase 2a TSC-related epilepsy study expected by Q1 2027 following FDA hold lift.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →